Insulin Regular IV Infusion and Pioglitazone and Glimepiride
Determining the interaction of Insulin Regular IV Infusion and Pioglitazone and Glimepiride and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.ADJUST DOSE: Coadministration of a sulfonylurea with insulin may potentiate the risk of hypoglycemia. Elderly, debilitated, or malnourished patients, and those with adrenal or pituitary insufficiency, are particularly susceptible to the hypoglycemic action of glucose-lowering drugs. MANAGEMENT: Caution and close blood glucose monitoring are advised during coadministration of these agents. A lower dosage of sulfonylurea or insulin may be required. Patients should be counseled to recognize the symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately and contact their physician. Patients should also be advised to take precautions to avoid hypoglycemia while driving or operating hazardous machinery. References "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY. "Product Information. Humulin R (insulin regular)." Lilly, Eli and Company, Indianapolis, IN. Cerner Multum, Inc. "Australian Product Information." O 0 "Product Information. Humulin N (insulin isophane)." Lilly, Eli and Company, Indianapolis, IN. "Product Information. Afrezza (insulin inhalation, rapid acting)." MannKind Corporation, Valencia, CA. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0 "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO. "Product Information. Amaryl (glimepiride)." Hoechst Marion-Roussel Inc, Kansas City, MO. "Product Information. NovoLIN R (insulin regular)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ. American Diabetes Association "9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2019" Diabetes Care 42 (2019): S90-S102 View all 10 references
Professional:ADJUST DOSE: Coadministration of a sulfonylurea with insulin may potentiate the risk of hypoglycemia. Elderly, debilitated, or malnourished patients, and those with adrenal or pituitary insufficiency, are particularly susceptible to the hypoglycemic action of glucose-lowering drugs.
MANAGEMENT: Caution and close blood glucose monitoring are advised during coadministration of these agents. A lower dosage of sulfonylurea or insulin may be required. Patients should be counseled to recognize the symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately and contact their physician. Patients should also be advised to take precautions to avoid hypoglycemia while driving or operating hazardous machinery.
- "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.
- "Product Information. Humulin R (insulin regular)." Lilly, Eli and Company, Indianapolis, IN.
- Cerner Multum, Inc. "Australian Product Information." O 0
- "Product Information. Humulin N (insulin isophane)." Lilly, Eli and Company, Indianapolis, IN.
- "Product Information. Afrezza (insulin inhalation, rapid acting)." MannKind Corporation, Valencia, CA.
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.
- "Product Information. Amaryl (glimepiride)." Hoechst Marion-Roussel Inc, Kansas City, MO.
- "Product Information. NovoLIN R (insulin regular)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.
- American Diabetes Association "9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2019" Diabetes Care 42 (2019): S90-S102
Generic Name: insulin regular
Brand name: Humulin R, Myxredlin, Novolin R, HumuLIN R KwikPen
Synonyms: Insulin Regular
Generic Name: glimepiride / pioglitazone
Brand name: Duetact
Synonyms: Glimepiride and pioglitazone
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Insulin Regular IV Infusion-Pioglitazone and Glimepiride Tablets
- Insulin Regular IV Infusion-Pioglitazone and metformin
- Insulin Regular IV Infusion-Pioglitazone and Metformin Extended-Release Tablets
- Insulin Regular IV Infusion-Pioglitazone and Metformin Tablets
- Insulin Regular IV Infusion-Pioglitazone Hydrochloride
- Insulin Regular IV Infusion-Pioglitazone Tablets
- Pioglitazone and Glimepiride-Insulin regular, concentrated U-500
- Pioglitazone and Glimepiride-Intal
- Pioglitazone and Glimepiride-Intal Inhaler
- Pioglitazone and Glimepiride-Intal Nebulizer Solution
- Pioglitazone and Glimepiride-Integra (Ferrous Fumarate, Polysaccharide Iron Complex, Vitamin C, and Vitamin B3)
- Pioglitazone and Glimepiride-Integra (Iron, Folic Acid, Vitamin C, and Vitamin B3)